| 영문 | angiotensin | 한글 | 안지오텐신 |
|---|---|---|---|
| 설명 | 콩팥에서 신장의 혈류와 혈압을 감지하는 세포인 치밀반점(macula densa)과 토리곁세포(JG cell)에서 혈류와 혈압의 저하가 있을 경우에 레닌이라는 물질이 분비되게 된다. 이 레닌이라는 물질은 혈중에 존재하는 안지오텐신이라는 물질을 안지오텐신 I으로 변화시키고 이 안지오텐신 I이라는 물질은 안지오텐신 I 전환효소에 의해서 안지오텐신II라는 물질로 된다. 안지오텐신과 안지오텐신 I이라는 물질은 그 작용이 거의 없지만 안지오텐신 II라는 물질은 강력하게 혈관수축을 시키고 이로 인해서 혈압의 상승을 가져오며 동시에 부신을 자극하여 알도스테론을 분비하게 한다. 안지오텐신이란 혈관을 수축시키고 알도스테론의 분비를 유도함으로써 혈압의 상승을 가져오는 물질이다. 그리고 그 작용은 레닌-안지오텐신-알도스테론으로 이어지는 체계에 의해서 조절되고 이루어진다. |
||
| 영문 | serum enzyme | 한글 | 혈청효소 |
|---|---|---|---|
| 설명 | 혈청 내에 포함되어 있는 여러 가지 효소를 일컫는 말이다. |
||
| 영문 | enzyme | 한글 | 효소 |
|---|---|---|---|
| 설명 | 생물체 세포속에서 합성되고, 주로 세포내에서 진행되는 화학반응을 촉매하는 단백질로 시험관내에서도 같은 촉매작용을 한다. 이 효소는 인공적으로 만든 어떤 촉매제보다 그 특이성과 촉매작용이 탁월한 특별한 생체분자이다. 신진대사, 즉 세포내에서 일어나는 물질의 화학적 변환은 효소의 작용에 의해 매우 빠르고 원할하게 이루어진다. 이것은 효소의 촉매 효율이 높은 점과 효소의 기질 특이성 때문이다. 효소반응은 상온, 상압, 최적 pH 등 적절한 조건 아래에서 진행된다. 또 효소의 주체가 단백질이기 때문에 단백질을 변성시키는 열, 강산, 강알칼리, 유기용매 등에 의해 그 작용을 잃는다. 효소는 생체에 널리 분포하며, 복잡하고 다양한 대사반응을 촉매하기 때문에 종류도 많다. 앞서 말한 바와 같이 대부분의 효소는 세포내에 존재하지만, 혈액과 그외의 간질액에 들어 있기도 하고 소화효소류처럼 체외로 분비되는 것도 있다. |
||
| 영문 | enzyme-linked immunoabsorbent assay | 한글 | 효소면역측정법 |
|---|---|---|---|
| 설명 | 효소결합면역흡착제 검정법으로 번역되고 있다. 이 법은 항원(또는 항체)에 알칼리 포스파타아제 또는 페르옥시디아제 등의 산소를 결합시켜 두고 그 산소활성을 지표로 삼아 항원항체반응의 정도를 안 다음 여기에서 항원(또는 항체)의 양을 구하는 것이다. 이 법의 이점으로서 고감도, 조작의 간단함 및 방사선면역측정법처럼 방사성물질을 사용하지 않아도 된다는 점을 들 수 있다. 호르몬이나 면역글로불린의 정량법으로서 응용 되고 있으며 측정용 키트도 시판되고 이있다. |
||
| ACE | Angiotensin Converting Enzyme = Kininase II = Dipeptidyl Carboxypepti... |
|---|---|
| ACE | acetonitrile; acetylcholine esterase; acute cerebral encephalopathy; acute coronary event; adrenocor... |
| PACE | Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic... |
| ACEDS | angiotensin-converting enzyme dysfunction syndrome |
| ACEI | angiotensin-converting enzyme inhibitor |
| ACE | ANGIOTENSIN CONVERTING ENZYME |
|---|---|
| ACE | Angiotensin converting enzyme activity |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
| ACE | angiotensin I converting enzyme gene |
| ACE | ANG I converting enzyme |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
|---|---|
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| angiotensin-converting enzyme secretase | <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline Registry number: EC 3.4.99.- Synonym: ace secretase (26 Jun 1999) |
| interleukin-1 converting enzyme | <biochemistry> Cytoplasmic cysteine protease that is uniquely responsible for cleaving proIL-1_ (31 or 33 kD) into mature IL-1_ (17.5 kD), the active cytokine is then released by a nonstandard mechanism (there is no signal sequence and it does not pass through the Golgi). The enzyme seems to be composed of two nonidentical subunits derived from a single proenzyme. The ICE gene has some homology with the ced 9 gene of C. Elegans, the product of which is involved in mediating cell death by apoptosis. (11 Mar 1998) |
| ACE | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| ACE level | <investigation> This is a blood test which measures the concentration of angiotensin-converting enzyme (ACE) in the bloodstream. Elevations in angiotensin-converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). (15 Jan 1998) |
| medication, ace-inhibitor | Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart. (12 Dec 1998) |
| vasopressin-converting aminopeptidase | <enzyme> Activity found in brain which converts vasopressin into centrally active metabolites Registry number: EC 3.4.11.- Synonym: vp-c aminopeptidase (26 Jun 1999) |
| dynorphin-converting endopeptidase | <enzyme> Enzyme from human cerebrospinal fluid; cleaves dynorphin a and b and neoendorphin at the arg(6)-arg(7) or arg(6)-lys(7) bonds Registry number: EC 3.4.21.- Synonym: dynorphin-neo-endorphin endopeptidase, dc-endopeptidase (26 Jun 1999) |
| urokinase-converting protease | <enzyme> Degrades synthetic urokinase substrates and stimulates urokinase Registry number: EC 3.4.21.- Synonym: urokinase cofactor (26 Jun 1999) |
| angiotensin | <hormone> A family of oligopeptides ranging in size from angiotensin precursors with 14 amino acids to the active vasoconstrictor angiotensin II with 8 amino acids, or their analogs or derivatives. The amino acid content varies with the species and changes in that content produce antagonistic or inactive compounds. Angiotensinogen (renin substrate) is a 60 kD polypeptide released from the liver and cleaved in the circulation by renin to form the biologically inactive decapeptide angiotensin I. This is in turn cleaved to form active angiotensin II by Angiotensin-converting Enzyme (ACE). Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. (12 Aug 2000) |
| angiotensin amide | <chemical> 1-l-asparagine-5-l-valine-angiotensin II. The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction. Pharmacological action: vasoconstrictor agents. Chemical name: Angiotensin II, 1-L-asparagine-5-L-valine- (12 Dec 1998) |
| angiotensin I | <chemical> The decapeptide precursor of angiotensin II, generated by the action of renin on angiotensinogen. It has limited pharmacologic activity. Chemical name: Angiotensin I (12 Dec 1998) |
| angiotensin II | <chemical> The active form of angiotensin. An octapeptide found in blood, it is synthesised from angiotensin I and quickly destroyed. Angiotensin II causes profound vasoconstriction with resulting increase in blood pressure. The clinically and experimentally used bovine form has valine in position 5 where the human form has isoleucine. Pharmacological action: vasoconstrictor agents. Chemical name: Angiotensin II (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|